Ancillary Educational Events

Meet the Professors — Clinical Investigator Perspectives on Key Questions and Emerging Research in the Management of Colorectal, Gastric and Hepatocellular Cancer

Date and Time: Friday, January 18, 2019, 6:30 PM (Dinner buffet to be provided)

Location: San Francisco Marriott Marquis, Yerba Buena Ballroom 9-15 (Lower B2 Level)

CME Provider and Supporter(s): This event is organized and accredited by Research To Practice and is supported by educational grants provided by Bayer HealthCare Pharmaceuticals, Eisai Inc., Lilly and Taiho Oncology Inc.

Registration and Contact Information: Register for the eventEmail for information or call (800) 233-6153 US Toll Free/ +1(305) 377-­2828.

Event Summary: This event will be segmented into three separate content modules, each focused on a different gastrointestinal (GI) malignancy, including colorectal, gastric and hepatocellular cancer. For each module, the meeting moderator, Dr. Neil Love, will be joined on stage by two clinical investigator faculty members. No didactic lectures will be utilized. Instead Dr. Love will lead an approximately 45-minute panel discussion during which the faculty members will review published clinical trial data, highlight ongoing research studies and present cases from their practices to illustrate the optimal application of the information introduced. Supporting data slides developed by Research To Practice will be integrated into the discussion. To make the program more interactive, clinician attendees will use iPads® to participate in a premeeting survey focused on the cases and topics presented, and the results will be interspersed throughout each module to foster additional debate.


Ghassan Abou-Alfa, MD
Memorial Sloan-Kettering Cancer Center

Eric Van Cutsem, MD, PhD
University Hospital Gasthuisberg/Leuven

David H. Ilson, MD, PhD
Memorial Sloan-Kettering Cancer Center

Additional faculty to be announced.

Neil Love, MD- Moderator
Research To Practice


Incorporating Immunotherapy Into Treatment for MSI-H/dMMR Colorectal Cancer: Latest Updates on Testing, Treatment, and irAE Management

Date and Time: Friday, January 18, 2019, 7:00 PM (Dinner and Registration begin at 6:30 PM)

Location: San Francisco Marriott Marquis, Yerba Buena Ballroom Salon 7

CE Provider and Supporter(s): This event is organized and accredited by Paradigm Medical Communications, LLC, and is supported by an educational grant provided by Bristol-Myers Squibb.

Registration and Contact Information: Register for the eventEmail for information or call (845) 398-5942.

Event Summary: Although immunotherapy has been available for other solid tumors since 2011, several immunotherapy regimens were recently approved for the treatment of relapsed/refractory CRC with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR), ushering in a new treatment paradigm. Because these agents are new to CRC, many oncology clinicians are not yet familiar with the latest clinical trial data or how to use these agents in clinical practice. In addition, many oncology clinicians are not familiar with the concept of MSI-H or dMMR, and therefore fail to follow universal testing guidelines. As a result, many patients do not receive testing and therefore may not receive immunotherapy. Furthermore, immunotherapy is associated with immune-related adverse events (irAEs), which are distinct from toxicities frequently observed with chemotherapy or targeted therapy. Many oncology clinicians still have difficulty recognizing and appropriately managing irAEs. Therefore, this activity with feature an expert-led, case-based discussion of biomarker testing, the latest on the use of immunotherapy, and managing potential irAEs in patients with CRC.


Michael J. Overman, MD
The University of Texas MD Anderson Cancer Center

Johanna Bendell, MD
Sarah Cannon Research Institute, Tennessee Oncology

Richard Kim, MD
Moffitt Cancer Center, University of South Florida College of Medicine